Trial · NCT00907257

A Study of Different Use Regimens Using Two Acne Treatments

NCT00907257, Phase 4, Completed, Bausch Health Americas, Inc.; results first posted 2011-01-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Different Use Regimens Using Two Acne Treatments. Trials, record NCT00907257. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00907257

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Different Use Regimens Using Two Acne Treatments
NCT number: NCT00907257
Status: Completed
Phases: Phase 4
Enrollment: 247 participants, actual
Lead sponsor: Bausch Health Americas, Inc.
Conditions: Acne Vulgaris
Interventions: benzoyl peroxide wash, Tretinoin gel
First posted: 2009-05-22
Last updated: 2012-02-15
Results first posted: 2011-01-21

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Total Facial Acne Lesion Count	Baseline to Week 12	Total Facial Acne Lesion Count is the sum of non-inflammatory and inflammatory lesions, plus nodules/cysts. Change from Baseline is calculated as the value after Baseline minus the baseline value, and negative values indicate improvement.
Secondary	Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Baseline to Week 12	Between group comparison with Last Count Carried Forward (LOCF) of Inflammatory Facial Acne Lesion Count (the sum of papules and pustules), Non-Inflammatory Facial Acne Lesion Count (the sum of open and closed comedones), and their Total (the sum of Non-inflammatory and Inflammatory lesions).
Secondary	Measurement of Success	Baseline to Week 12	Number of subjects achieving success according to dichotomized Investigator Global Assessment (IGA) using criteria of grades 0 or 1, or improvement of 2 grades from baseline score. Possible grades from 0-6 are described as follows: 0 = Clear, 1=Almost Clear, 2=Mild, 3=Mild to Moderate, 4=Moderate, 5=Moderately Severe, 6=Severe.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Total Facial Acne Lesion Count	Baseline to Week 12	Per Protocol Population, which includes all Intention to Treat (ITT) subjects who completed the 12 weeks of treatment and evaluations with no major protocol deviations.	Lesions	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Baseline to Week 12	Data set includes all Intent to Treat (ITT)subjects. Imputation technique was Last Observation Carried Forward (LOCF).	Lesions	LEAST_SQUARES_MEAN
SECONDARY	Measurement of Success	Baseline to Week 12	Intention to Treat (ITT)population and imputation technique of Last Observations Carried Forward (LOCF)	Participants	NUMBER

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in Total Facial Acne Lesion Count	Same Time of Day		39.74	Standard Error 1.64	Lesions
Change From Baseline in Total Facial Acne Lesion Count	Different Times of Day		40.02	Standard Error 1.62	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Same Time of Day	Inflammatory Lesions	14.6	Standard Error 0.85	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Different Times of Day	Inflammatory Lesions	14.2	Standard Error 0.84	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Same Time of Day	Non-Inflammatory Lesions	23.2	Standard Error 1.17	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Different Times of Day	Non-Inflammatory Lesions	23.7	Standard Error 1.16	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Same Time of Day	Total Lesions	37.4	Standard Error 1.70	Lesions
Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals	Different Times of Day	Total Lesions	38.1	Standard Error 1.68	Lesions
Measurement of Success	Same Time of Day	Clear / Almost Clear	26		Participants
Measurement of Success	Different Times of Day	Clear / Almost Clear	25		Participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Same Time of Day	123
Overall Study	STARTED	Different Times of Day	124
Overall Study	COMPLETED	Same Time of Day	110
Overall Study	COMPLETED	Different Times of Day	112
Overall Study	NOT COMPLETED	Same Time of Day	13
Overall Study	NOT COMPLETED	Different Times of Day	12

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
serious	Cardiac Arrhythmia	Cardiac disorders	Same Time of Day	1	123
serious	Cardiac Arrhythmia	Cardiac disorders	Different Times of Day	0	124
serious	Viral Myocarditis	Cardiac disorders	Same Time of Day	1	123
serious	Viral Myocarditis	Cardiac disorders	Different Times of Day	0	124
serious	Ovarian Cyst	Reproductive system and breast disorders	Same Time of Day	1	123
serious	Ovarian Cyst	Reproductive system and breast disorders	Different Times of Day	0	124

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Same Time of Day
Total, all-cause mortality	Different Times of Day
Total, other adverse events	Same Time of Day	0	123
Total, other adverse events	Different Times of Day	0	124
Total, serious adverse events	Same Time of Day	3	123
Total, serious adverse events	Different Times of Day	0	124

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20677537	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Same Time of Day vs Different Times of Day: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00907257

GET https://conductscience.org/api/trials/v1/NCT00907257/registered

API reference For AI assistants